echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Treatment of migraine compound preparation sorority is stronger than single-drug treatment

    Treatment of migraine compound preparation sorority is stronger than single-drug treatment

    • Last Update: 2020-07-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Two recent trials conducted in the United Statesshowed that the naproxen/sumatriptan compound was more effective at treating migraines than using either drug aloneIn the two multicenter studies, the researchers analyzed drug efficacy data for 1441 (study 1) and 1470 (study 2) patientsThese patients received outpatient treatment for only one type of migraine and followed up for 1 to 5 days after treatmentPatients were randomly divided into four groups in a ratio of 1:1:1, and were treated with a single dose of psipurin/Shumuptan compound preparations of 500 mg/85 mg, psiproprical 500 mg, Shumuptan 85 mg or placeboThe patient can receive first aid treatment two hours after the treatment has been completedTwo hours after treatment, the use of fentanol/Shumapitan was significantly effective in reducing headaches (study 1,65 percent vs28 percent; study 2,57 percent vs29 percent), loss of light symptoms (study 1,58 percent vs36 percent; study 2,50 percent vs32 percent) and phobia (study 1,61 percent vs38 percent); study 2,56 percent to 34 percent)Compared to the placebo group, the rate of nausea symptoms disappeared significantly (71% vs65%) in the study 1 group after two hours of treatment (71% vs65%), and there was no significant difference between the two groups in study 2 (65% vs64%)In addition, the proportion of headache-free responses in the psiphon/Shumaptan group for 24 hours was significantly higher than in the study group (study 1,25% vs 16%) and the pupgengroup (study 1,25% vs 10%) and study 2,23% vs 10%) (Yang Minyan)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.